Clinical Trials
10
Active:1
Completed:8
Trial Phases
2 Phases
Phase 1:6
Not Applicable:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (60.0%)Not Applicable
4 (40.0%)Influenza a (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)
Phase 1
Active, not recruiting
- Conditions
- H7N9 Influenza
- Interventions
- Combination Product: Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA)Combination Product: Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA)Biological: Adjuvanted Influenza A (H7N9) Monovalent Vaccine InjectionCombination Product: Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant)Combination Product: Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant)Combination Product: Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant)Combination Product: Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant)Device: Microarray Patch Delivery System
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Vaxxas Pty Ltd
- Target Recruit Count
- 267
- Registration Number
- NCT06417853
- Locations
- 🇦🇺
University of Sunshine Coast Clinical Trials, South Brisbane, Queensland, Australia
🇦🇺Doherty Clinical Trials Ltd, East Melbourne, Victoria, Australia
News
No news found